Determinants for drug survival of methotrexate in patients with psoriasis, split according to different reasons for discontinuation: results of the prospective MTX‐CAPTURE

As methotrexate (MTX) is a widely used treatment for psoriasis, it is important to gain insight into the reasons for the discontinuation of MTX and to understand the determinants for drug survival.

[1]  W. Kievit,et al.  Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side‐effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long‐term drug‐survival study from the BioCAPTURE r , 2016, The British journal of dermatology.

[2]  F. Vanaclocha,et al.  Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  P. C. van de Kerkhof,et al.  Effectiveness of Biologic and Conventional Systemic Therapies in Adults with Chronic Plaque Psoriasis in Daily Practice: A Systematic Review. , 2016, Acta dermato-venereologica.

[4]  A. Menter,et al.  Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[5]  R. Caporali,et al.  Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration , 2016, Advances in Therapy.

[6]  P. Gisondi,et al.  European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  I. Harman-boehm,et al.  Factors associated with drug survival of methotrexate and acitretin in patients with psoriasis. , 2015, Acta Dermato-Venereologica.

[8]  A. Burden,et al.  Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). , 2015, The Journal of investigative dermatology.

[9]  J. Goeman,et al.  Drug Survival Studies in Dermatology:Principles, Purposes, and Pitfalls. , 2015, The Journal of investigative dermatology.

[10]  S. Goodman,et al.  Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review. , 2015, Clinical and experimental rheumatology.

[11]  L. Skov,et al.  Comparison of long‐term drug survival and safety of biologic agents in patients with psoriasis vulgaris , 2015, The British journal of dermatology.

[12]  L. Skov,et al.  Discontinuation of methotrexate in psoriasis. , 2012, Acta dermato-venereologica.

[13]  Å. Svensson,et al.  Patients' visual analogue scale: a useful method for assessing psoriasis severity. , 2012, Acta dermato-venereologica.

[14]  L. Naldi,et al.  European S3‐Guidelines on the systemic treatment of psoriasis vulgaris , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[15]  C. Main,et al.  Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. , 2003, Archives of dermatology.

[16]  J. Cohn,et al.  Psychological Distress , 1998, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[17]  G. Alarcón,et al.  Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. , 1995, Annals of the rheumatic diseases.

[18]  L. Hooft,et al.  Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the Use of Test-dose, Start-dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic Acid Supplementation. , 2016, Acta dermato-venereologica.